The Neurovascular Devices Market is witnessing steady expansion as healthcare providers increasingly rely on minimally invasive technologies for diagnosing and treating complex cerebrovascular disorders. The market was valued at USD 5.17 billion in 2025 and is projected to reach USD 10.48 billion by 2035, expanding at a CAGR of 8.22% during 2026–2035.

One of the strongest contributors to market growth is the increasing adoption of mechanical thrombectomy for acute ischemic stroke. Improvements in clinical guidelines and patient-selection methods have expanded the number of patients eligible for endovascular intervention. Neurothrombectomy devices are expected to be among the fastest-growing product categories, with a projected CAGR of 9.14% through 2035.

Technological innovation is also changing the neurovascular treatment landscape. Advanced aspiration catheters, stent retrievers, flow diverters, embolization systems, and intracranial stents are being developed to improve procedural precision and patient outcomes. AI-assisted decision support and robotic catheter-navigation technologies are further creating opportunities for manufacturers seeking to differentiate their products.

Hospitals remain the primary end users because complex neuro-interventional procedures require specialized imaging systems, catheterization laboratories, intensive-care facilities, and trained specialists. Hospitals represented approximately 63% of the market in 2025, while ambulatory surgical centers are expected to experience faster growth as selected elective procedures increasingly move into outpatient settings.

Geographically, North America remains the leading regional market, accounting for approximately 47.2% of revenues in 2025. Asia-Pacific is expected to record the fastest growth, supported by investments in stroke-ready infrastructure, increasing healthcare expenditure, and growing awareness of advanced cerebrovascular treatments.